Evidence supporting the enhanced efficacy of pentavalent antimonials with adjuvant therapy for cutaneous leishmaniasis: a systematic review and meta-analysis.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
06
08
2019
accepted:
10
02
2020
pubmed:
3
3
2020
medline:
15
5
2021
entrez:
3
3
2020
Statut:
ppublish
Résumé
Cutaneous leishmaniasis (CL) is one of the major neglected disease worldwide. Although many drugs have been used, the pentavalent antimonials (PA) remain as the first-line choice despite their toxicity and limited efficacy. The combination of two drugs has risen as a potential alternative to increase the cure rate while lowering the side-effects caused by pentavalent antimonials (PA). The objective of this study was to critically review and appraise the potential synergism of the adjuvant therapies of PA with other drugs/interventions previously used in the literature. We carried out a search of literature from PubMed, MEDLINE, Embase, Cochrane and clinicaltrials.gov. Articles that described a two-arm or three-arm design in which one of the arms consisted in a combination of a drug/intervention with intralesional or systemic PA were selected. The primary outcome was proportion of complete clearance of the lesions defined as complete re-epithelization and/or negative direct smear. Our literature search identified 554 references. Thirty-one records with a total sample size of 2668 participants met the eligibility criteria. The studies investigated the association of PA with the following: cryotherapy (five studies), allopurinol, imiquimod, pentoxifylline (four studies each), trichloroacetic acid 50% (three studies) and other additional interventions (eleven studies). Overall, the combined therapy of PA with a supplementary intervention was superior to PA monotherapy (RR: 1.23 95% CI: 1.11-1.35, I
Substances chimiques
Imiquimod
P1QW714R7M
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2216-2228Informations de copyright
© 2020 European Academy of Dermatology and Venereology.
Références
https://www.who.int/features/qa/58/en/.
https://www.who.int/news-room/fact-sheets/detail/leishmaniasis. Accessed in May 2019.
Bennis I, De Brouwere V, Belrhiti Z, Sahibi H Boelaert M. Psychosocial burden of localised cutaneous Leishmaniasis: a scoping review. BMC Public Health 2018; 18: 358.
Tuon FF, Amato VS, Graf ME, Siqueira AM, Nicodemo AC Amato NV. Treatment of New World cutaneous leishmaniasis - a systematic review with a meta-analysis. Int J Dermatol 2008; 47:109-124.
Alcântara LM, Ferreira TCS, Gadelha FR Miguel DC. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis. Int J Parasitol Drugs Drug Resist 2018; 8: 430-439.
Frézard F, Demicheli C Ribeiro RR. Pentavalent antimonials: new perspectives for old drugs. Molecules 2009; 14: 2317-2336.
Blum J, Lockwood DN, Visser L et al. Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. International Health 2012; 4: 153-163.
Kevric I, Cappel MA Keeling JH. New world and old world leishmania infections: a practical review. Dermatol Clin 2015; 33: 579-593.
Cuestas D, Forero Y, Galvis I et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) and multiple organ dysfunction syndrome (MODS): one more reason for a new effective treatment against leishmaniasis. Int J Dermatol 2018; 57: 1304-1313.
Ponte-Sucre A, Gamarro F, Dujardin JC et al. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis 2017; 11: e0006052.
Burza S, Croft SL Boelaert M. Leishmaniasis. Lancet 2018; 392: 951-970.
Heras-Mosteiro J, Monge-Maillo B, Pinart M et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2017; 12: CD005067.
Gonzalez U, Pinart M, Reveiz L et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2008; 4: CD005067.
Gonzalez U, Pinart M, Rengifo-Pardo M et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009; 2: CD004834.
Hodiamont CJ, Kager PA, Bart A et al. Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide. PLoS Negl Trop Dis 2014; 8: e2832. eCollection 2014 May.
Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items forsystematic reviews and meta-analyses: the PRISMA Statement. OpenMed 2009; 3: e123-130.
Deeks J, Higgins J, Altman D Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0 (updated March 2011). London: The Cochrane Collaboration 2011.
el Darouti MA, al Rubaie SM. Cutaneous leishmaniasis. Treatment with combined cryotherapy and intralesional stibogluconate injection. Int J Dermatol 1990; 29: 56-59.
Asilian A, Sadeghinia A, Faghihi G, Momeni A Amini HA. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol 2003; 97: 493-498.
Asilian A, Sadeghinia A, Faghihi G Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneousleishmaniasis. Int J Dermatol 2004; 43: 281-283.
Salmanpour R, Razmavar MR Abtahi N. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45: 1115-1116.
van Thiel PP, Leenstra T, de Vries HJ et al. Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects, and treatment. Am J Trop Med Hyg 2010; 83: 1295-1300.
Esfandiarpour I Alavi A. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 2002; 41: 521-524.
Martinez S Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992; 326: 741-744.
Martinez S, Gonzalez M Vernaza ME. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin Infect Dis 1997; 24: 165-169.
Momeni AZ, Reiszadae MR Aminjavaheri M. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate. Int J Dermatol 2002; 41: 441-443.
Arevalo I, Tulliano G, Quispe A et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007; 44: 1549-1554.
Firooz A, Khamesipour A, Ghoorchi MH et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol 2006; 142: 1575-1579.
Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 2005; 40: 1395-1403.
Miranda-Verastegui C, Tulliano G, Gyorkos TW et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis 2009; 3: e491.
Brito G, Dourado M, Polari L et al. Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. Am J Trop Med Hyg 2014; 90: 617-620.
Brito G, Dourado M, Guimarães LH et al. Oral pentoxifylline associated with pentavalent antimony: a randomized trial for cutaneous leishmaniasis. Am J Trop Med Hyg 2017; 96: 1155-1159.
Cossio-Duque A, Del Mar Castro M, Navas A et al. Effect of the addition of pentoxifylline on the therapeutic and inflammatory response in patients with cutaneous leishmaniasis: A randomized placebo controlled trial. Am J Tropical Med Hygiene 2015; 93(4 Supplement): 536.
Sadeghian G Nilforoushzadeh MA. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45: 819-821.
Ejaz Q, Saleem S Akbar N. Comparison of efficacy of intralesional meglumine antimoniate vs. combination of 50% trichloroacetic acid and intralesional meglumine antimoniate in patients of cutaneous leishmaniasis. J Pakistan Assoc Dermatol 2018; 28: 426-430.
Jaffary F, Nilforoushzadeh MA, Siadat A, Haftbaradaran E, Ansari N Ahmadi E. A comparison between the effects of glucantime, topical trichloroacetic acid 50% plus glucantime, and fractional carbon dioxide laser plus glucantime on cutaneous leishmaniasis lesions. Dermatol Res Pract 2016; 2016: 6462804.
Nilforoushzadeh MA, Nilforoushzadeh MA, Jaffary F et al. Comparison between intralesional meglumine antimoniate and combination of trichloroacetic acid 50% and intralesional meglumine antimoniate in the treatment of acute cutaneous leishmaniasis: A randomized clinical trial. J Skin Stem Cell 2014; 1 Article Number: e16633.
Machado PRL, Ribeiro CS, França-Costa J et al. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial. Trop Med Int Health 2018; 23: 936-942.
Shanehsaz SM Ishkhanian S. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis. Int J Dermatol 2015; 54: 834-838.
Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z Firouz A. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis. J Vector Borne Dis 2008; 45: 287-291.
El-Sayed M Anwar AE. Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study. J Eur Acad Dermatol Venereol 2010; 24: 335-340.
Farajzadeh S, Heshmatkhah A, Vares B et al. Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial. J Parasit Dis 2016; 40: 1159-1164.
Shazad B, Abbaszadeh B Khamesipour A. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur J Dermatol 2005; 15: 85-87.
Almeida R, D'Oliveira A Jr, Machado P et al. Randomized, double-blind study of stibogluconate plus human granulocytemacrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous Leishmaniasis. J Infect Dis 1999; 180: 1735-1737.
Arana BA, Navin TR, Arana FE, Berman JD Rosenkaimer F. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clin Infect Dis 1994; 18: 381-384.
Nilforoushzadeh MA, Jaffary F, Moradi S, Derakhshan R Haftbaradaran E. Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis. BMC Complement Altern Med 2007; 27: 13.
Khatami A, Talaee R, Rahshenas M et al. Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial. PLoS One 2013; 8: e66123.
Maleki M, Rakhshande H, Layegh P, Mashayekhi V, Seyedi S. A comparison between intralesional glucantime and combined use of topical Berberis vulgaris root extracts and intralesional glucantime in the treatment of cutaneous leishmaniasis. Avicenna J Phytomed 2015; 5: 76. 2/3p.
Weil GJ, Bogus J, Christian M et al. DOLF IDA Safety Study Group. The safety of double- and triple-drug community mass drug administrationfor lymphatic filariasis: A multicenter, open-label, cluster-randomized study. PLoS Med 2019; 16: e1002839.
Knopp S, Person B, Ame SM et al. Evaluation of integrated interventions layered on mass drug administration for urogenital schistosomiasis elimination: a cluster-randomised trial. Lancet Glob Health 2019; 7: e1118-e1129 pii: S2214-109X(19)30189-5.
Berbert TRN, de Mello TFP, Wolf Nassif P et al. Pentavalent antimonials combined with other therapeutic alternatives for the treatment of cutaneous and mucocutaneous leishmaniasis: a systematic review. Dermatol Res Pract 2018; 24: 9014726.
Brito NC, Rabello A Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS One 2017; 12: e0184777.
Blum J, Buffet P, Visser L et al. LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014. J Travel Med 2014; 21: 116-129.
Aronson N, Herwaldt BL, Libman M et al. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2016; 63: e202-e264.
Soto J, Rojas E, Guzman M et al. Intralesional antimony for single lesions of Bolivian cutaneous leishmaniasis. Clin Infect Dis 2013; 56: 1255-1260.
Kimura A, Kanazawa N, Li HJ, Yonei N, Yamamoto Y, Furukawa F. Influence of chemical peeling on the skin stress response system. Exp Dermatol 2012; 21: 8-10.
Siadat A, Jaffary F, Nilforoushzadeh M, Ansari N Moradi S. The comparison between trichloroacetic acid 50% and CO2 laser in the treatment of cutaneous leishmaniasis scar. Indian J Dermatol 2011; 56: 171-173.
Avishai E, Yeghiazaryan K Golubnitschaja O. Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine. EPMA J 2017; 8: 23-33.
Chawla B Madhubala R. Drug targets in Leishmania. J Parasit Dis 2010; 34: 1-13.
Yasur-Landau D, Jaffe CL, David L, Doron-Faigenboim A Baneth G. Resistance of Leishmania infantum to allopurinol is associated with chromosome and gene copy number variations including decrease in the S-adenosylmethionine synthetase (METK) gene copy number. Int J Parasitol Drugs Drug Resist 2018; 8: 403-410.
Machado PR, Lessa H, Lessa M et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007; 44:788-793.
Lessa HA, Machado P, Lima F et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. AmJ TropMed Hyg 2001; 65:87-89.